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Introduction
Malaria is one of the most widespread and devastating infectious 
diseases affecting the world community, causing 216 million 
clinical cases and 0.665 to 1.24 million deaths in 2010.1,2 A 
highly effective vaccine remains elusive, awaiting new insights 
When introduced in the 1990s, immunization with DNa plasmids was considered potentially revolutionary for vaccine 
development, particularly for vaccines intended to induce protective cD8 T cell responses against multiple antigens. We 
conducted, in 1997–1998, the first clinical trial in healthy humans of a DNa vaccine, a single plasmid encoding Plasmodium 
falciparum circumsporozoite protein (Pfcsp), as an initial step toward developing a multi-antigen malaria vaccine targeting 
the liver stages of the parasite. as the next step, we conducted in 2000–2001 a clinical trial of a five-plasmid mixture 
called MustDO5 encoding pre-erythrocytic antigens Pfcsp, Pfssp2/TRap, PfeXp1, PfLsa1 and PfLsa3. Thirty-two, malaria-
naïve, adult volunteers were enrolled sequentially into four cohorts receiving a mixture of 500 μg of each plasmid plus 
escalating doses (0, 20, 100 or 500 μg) of a sixth plasmid encoding human granulocyte macrophage-colony stimulating 
factor (hGM-csF). Three doses of each formulation were administered intramuscularly by needle-less jet injection at 0, 4 
and 8 weeks, and each cohort had controlled human malaria infection administered by five mosquito bites 18 d later. The 
vaccine was safe and well-tolerated, inducing moderate antigen-specific, MHc-restricted T cell interferon-γ responses 
but no antibodies. although no volunteers were protected, T cell responses were boosted post malaria challenge. This 
trial demonstrated the MustDO5 DNa and hGM-csF plasmids to be safe and modestly immunogenic for T cell responses. 
It also laid the foundation for priming with DNa plasmids and boosting with recombinant viruses, an approach known 
for nearly 15 y to enhance the immunogenicity and protective efficacy of DNa vaccines.
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into malaria biology, clearer definition of protective immune 
mechanisms and target antigens, and development of novel 
vaccine approaches or platforms. Progress to date is exemplified 
by the leading vaccine candidate, RTS,S, which reduced the 
incidence of first episodes of clinical P. falciparum malaria in 
African children by about 50% during the initial 12 mo of a 
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DNA prime, recombinant virus approach also induced protec-
tion in non-human primates.16
More recently, poxvirus-vectored vaccines expressing CSP or 
other pre-erythrocytic stage malaria proteins have likewise shown 
promise in humans, and adenovirus-vectored vaccines in animals 
and in humans, in some instances generating IFNγ-secreting T 
cell responses that correlated with protection.17-22 These other 
antigens include apical membrane antigen-1 (AMA1)23 and 
thrombospondin-related adhesive protein/sporozoite surface 
protein-2 (TRAP/SSP2)24,25 either expressed by sporozoites but 
carried into the hepatocyte on invasion or first expressed in the 
hepatocyte and potentially expressed on the hepatocyte surface in 
the context of MHC class I.
We hypothesized that by combining the DNA sequences 
encoding multiple antigens, protective effects may be additive 
or synergistic to achieve high grade immunity in a majority of 
vaccine recipients.26,27 As an initial step prior to assessing the 
multi-antigen approach and the prime boost approach, we 
tested a monovalent plasmid vaccine encoding PfCSP in two 
Phase 1 studies in humans. The PfCSP vaccine did not induce 
CSP antibodies,28,29 but did induce antigen-specific, cytotoxic 
T cell responses (CTL) to HLA-restricted synthetic peptides 
in 11/20 volunteers expressing HLA-A02 supertype alleles that 
were dependent on CD8+ T cells in depletion studies.29,30 The 
next step was development of the pentavalent DNA vaccine 
called MuStDO5 (Multi-Stage DNA Vaccine Operation, 5 
genes)31 designed to test the multivalent approach, comprising a 
mixture of plasmids each encoding a different pre-erythrocytic 
stage P. falciparum antigen (3D7 strain). These were PfCSP,32 
Pf TRAP/SSP2, Pf exported protein-1 (Pf Exp1),33 N’ and C’ 
terminus of Pf liver stage antigen-1 (Pf LSA1)34 and Pf liver 
stage antigen-3 (Pf LSA3).35 To improve the immunogenicity 
of the five-plasmid mixture, a sixth plasmid encoding human 
granulocyte macrophage-colony stimulating factor (hGM-CSF) 
was added, based on enhanced protection in murine models 
when a plasmid encoding murine GM-CSF was combined 
with other plasmids encoding malaria antigens.36 hGM-CSF 
recombinant protein had previously been approved by the FDA 
as a hematopoietic growth factor, and had been used in clinical 
vaccine trials as an adjuvant,37 where it was hypothesized to act 
by binding to a specific cytokine α/β receptor.38
The clinical trial reported here aimed to establish safety, 
tolerability and immunogenicity of the MuStDO5 vaccine, 
and also to test for efficacy against malaria by allowing infected 
mosquitoes to bite the immunized volunteers followed by active 
surveillance for parasitemia (controlled human malaria infection 
or CHMI). We co-administered the five DNA plasmids with 
or without the plasmid encoding hGM-CSF, having previously 
demonstrated safety in preclinical studies.39 Because this was 
a first-in-humans study for four of the five malaria plasmids 
(excepting the PfCSP plasmid) and for the hGM-CSF plasmid, 
a four cohort, dose escalation design was used, with cohort 
1 receiving 2,500 μg of the MuStDO5 cocktail (500 μg each 
plasmid) in phosphate buffered saline and cohorts 2, 3 and 4 
receiving 2,500 μg of MuStDO5 mixed with 20 μg, 100 μg or 
500 μg of the hGM-CSF plasmid, respectively. The initiation of 
Phase 3 efficacy trial.3 While this landmark result is encouraging, 
significant improvements over current vaccine candidates are 
needed to induce the complete, sustained immunity required 
for campaigns to eliminate malaria and to prevent malaria in 
travelers, military personnel and multiple other populations in 
endemic countries.
RTS,S represents one approach to developing a malaria vac-
cine, based primarily on the induction of protective antibody 
responses. The vaccine contains recombinant circumsporozoite 
protein (CSP), the major surface antigen of the P. falciparum 
sporozoite; CSP is bound in a matrix containing hepatitis B sur-
face antigen and adjuvant to enhance immunogenicity. This for-
mulation induces very strong anti-sporozoite antibody responses 
that are thought to limit sporozoite motility and the capacity 
to invade hepatocytes, thereby preventing liver stage infection. 
While CD4+ T cells are also induced and likely serve a helper 
function in the induction of protective antibodies as well as in 
secretion of interferon-gamma (IFN-γ), RTS,S does not induce 
CD8+ T cells.4
An alternative approach to malaria vaccines aims to directly 
target infected hepatocytes via cell-mediated immunity (CMI). 
The most profound, sustained protective immunity in humans 
has been induced by immunization with whole sporozoites 
administered by mosquito bites.5-9 In animal models, this immu-
nity is dependent on CD8+ T cells, including when aseptic, puri-
fied, cryopreserved sporozoites are used to immunize.10 Thus, 
for more than two decades there has been a significant effort 
to develop subunit vaccines that induce protective CD8+ T cell 
responses against antigens expressed in infected hepatocytes. 
Studies in animal models indicate that CD8+ cells can recognize 
CSP-derived peptides on the surface of the infected host cell in 
the context of MHC class I, leading to the release of toxic mate-
rials such as granzyme and perforin, which lyse the target cell, 
and/or to the secretion of IFNγ,11,12 which induces the infected 
hepatocyte to produce NO leading to the death of the para-
site. To induce CD8+ T cell immunity, vaccine developers have 
turned to platforms such as DNA plasmids or viral vectors that 
deliver the genes encoding the malaria antigens rather than the 
antigens themselves. After being taken up by host cells, the DNA 
is transcribed and translated, leading to intracellular expression 
of the malaria proteins. This activates the endogenous antigen 
presentation pathway, inducing cell-mediated immune responses 
including CD8+ T cells able to target developing intracellular 
liver stage parasites. An advantage of the DNA approach is the 
capacity to rapidly and efficiently produce plasmids expressing 
multiple proteins.
The first DNA malaria vaccine, based on PfCSP was studied 
by our group in the mid-1990s in mice and induced sterile pro-
tection against the murine malaria P. yoelii.13,14 Protection was 
dependent upon CD8+ T cells, as shown by the loss of protec-
tion following CD8+ T cell depletion in vivo. Cytotoxic T lym-
phocyte (CTL) assays showed genetically-restricted, CSP-specific 
killing of target cells in vitro.14 We next showed in mice that this 
protection could be enhanced by priming with the PyCSP DNA 
plasmid and boosting with a recombinant poxvirus expressing 
PyCSP.15 This was followed by a studying demonstrating that this 
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of the cohorts. A few additional class I antigens were identified; 
however, matched peptides were not available for these.
Cohorts 1 and 2 received their first immunizations on 03 and 
20 Nov 2000, respectively, while cohorts 3 and 4 received their 
first immunizations on 23 Jan and 20 Feb 2001, respectively. 
One HLA-A02 vaccinee from cohort 3 withdrew after the first 
immunization (personal reason not related to adverse events) and 
was not replaced, reducing the sample size of vaccinees from 8 to 
7 in cohort 3 (from 32 to 31 overall), and one infectivity control 
from cohort 1 withdrew prior to challenge (due to personal 
reasons not related to adverse events) and was replaced by the extra 
volunteer (see above). Forty-four volunteers were challenged in 
four separate challenges, 31 vaccine recipients and 13 infectivity 
controls. Six of these 44 participants missed the week 24 visit (94 
d post challenge) and/or week 52 visit (290 d post challenge): 2 
were lost to follow-up, 3 were military transfers, and 1 moved out 
of area. The final cohort composition, including demographics, 
is provided in Table 1.
Safety. Thirty-one volunteers received three immunizations 
and one volunteer in cohort 3 received one immunization, 
totaling 94 doses of MuStDO5 and 24, 22 and 24 doses of 
MuStDO5 combined with hGM-CSF at 20 μg, 100 μg or 500 
μg, respectively. Adverse events were assessed on days 2, 7, 14 
and 28 post first and second immunizations, and on days 2, 7 
and 14 post third immunizations (CHMI was initiated on day 
18 precluding additional observation for vaccine effects). Adverse 
events were classified as definitely, probably, possibly related or 
unrelated to vaccine administration, and also classified according 
to severity grade as mild, moderate or severe.
Solicited adverse events. 112 solicited local adverse events 
were classified as definitely related to vaccine administration 
(Table 2): injection site tenderness (69 cases), injection site 
pain (14 cases), injection site erythema (10 cases), injection 
site ecchymosis (8 cases), injection site induration (7 cases), 
injection site swelling (1 case), injection site pruritis (1 case), 
decreased arm range of motion (1 case) and ipsilateral muscle 
ache in the neck (1 case). Of these 112 adverse events, 104 were 
classified as mild (grade 1) and 8 as moderate (grade 2). In 
addition, there were 51 solicited systemic adverse events. None 
were categorized as definitely related to vaccine administration, 
indicating very favorable tolerability. Three were classified as 
probably related to vaccine administration: 2 cases of arthralgia 
and 1 case of general myalgia, each classified as mild (grade 
1). The remaining 48 systemic adverse events were classified 
as possibly related to immunization: one case of vomiting was 
classified as moderate in severity (grade 2), while the other 
47 were classified as mild in severity (grade 1), and included 
myalgia (3 cases), malaise (5 cases), headache (10 cases), 
diarrhea (3 cases), nausea (4 cases), fatigue (2 cases), arthralgia 
(1 case), chills (4 cases), lightheadedness/dizziness (3 cases), 
chest tightness (1 case), respiratory symptoms (10 cases) and 
fever (1 case). These possibly related systemic adverse events 
appeared more likely related to intercurrent respiratory and 
other illnesses experienced by the volunteers rather than to the 
vaccine. All these adverse events resolved within two or three 
days of vaccine administration. There were no solicited severe 
each cohort was staggered to allow assessment of safety prior to 
testing the next higher dose of hGM-CSF DNA.
Thirty-one malaria-naïve and healthy adult research vol-
unteers received three doses of the vaccine by intramuscular 
jet injection (Biojector® 2000) into alternating arms and were 
assessed for efficacy in four separate challenges with P. falciparum 
sporozoites (CHMI) conducted 18 d after the third DNA immu-
nization. Although no volunteers were sterilely protected, the 
vaccine was safe and well-tolerated and induced IFNγ responses 
to HLA-matched peptides derived from all five antigens.31 IFNγ 
responses were boosted on exposure to parasites during chal-
lenge. This report presents safety, tolerability and antibody 
responses, and summarizes IFNγ ELISpot responses, which have 
been reported in detail elsewhere,31 and also describes the out-
come of CHMI.
Results
The primary objective of this study was to determine the safety 
and tolerability of MuStDO5 in combination with escalating 
dose hGM-CSF plasmid in healthy, malaria-naïve, adult volun-
teers. The secondary objectives were to measure immunogenicity 
and protection against sporozoite challenge.
Participant flow. The target sample size was eight vaccin-
ees and three infectivity controls in each cohort; since no ster-
ile protection was seen in the first three cohorts, the number of 
infectivity controls was expanded to four in the fourth cohort to 
increase power to identify delayed onset of parasitemia in vac-
cine recipients. 102 adult male and female volunteers age 18–50 
provided informed consent and 57 of these passed screening and 
were determined to be eligible after 12 decided to withdraw (rea-
son not specified by volunteer) and 33 were excluded (Fig. 1). Ten 
additional volunteers withdrew prior to the first immunization 
(Fig. 1). The 47 remaining volunteers were assigned sequentially 
to four cohorts assessing MuStDO5 alone or MuStDO5 plus one 
of the three doses of hGM-CSF-encoding plasmid (32 vaccinees 
and 15 non-vaccinated controls). One of the 15 non-vaccinated 
controls was enrolled as an extra volunteer to replace any infec-
tivity control drop-outs, one was enrolled as a source of malaria-
naïve peripheral blood mononuclear cells (PBMC) for cohort 4 
(immunological control) and 13 were enrolled as infectivity con-
trols or as both infectivity controls and immunological controls.
HLA alleles were distributed among the four cohorts based 
on the need to match volunteer HLA types in each cohort 
with a set of strongly-binding peptides identified from the five 
malaria antigens that were restricted by common HLA class I 
antigens. HLA-A02 and HLA-A03 supertypes were fairly evenly 
distributed among vaccinees meeting enrollment targets (see 
Methods) comprising, respectively, 5 and 3 volunteers in the 
first cohort, 3 and 6 volunteers in the second cohort, 3 and 4 
volunteers in the third cohort, and 4 and 7 in the fourth cohort. 
Thus 15/32 (47%) and 20/32 (63%) of volunteers expressed 
HLA-A02 and/or HLA-A03 supertypes overall, comprising all 
but four (13%) of the research subjects. HLA-A01 and HLA-
B07 supertypes were also represented in each cohort, while 
HLA-A24 and HLA-B08 supertypes were represented in some 
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unexpected adverse events identified. Three were classified 
as unrelated to immunization: (1) New onset peptic ulcer 
disease in a control volunteer (severity grade 3); (2) Erythema 
multiforme in a cohort 2 volunteer, likely associated with oral 
herpes reactivation following malaria infection or possibly 
with administration of chloroquine or prochlorperazine during 
malaria treatment (severity grade 2); (3) Orthostatic hypotension 
in a cohort 1 volunteer during acute malaria infection (severity 
grade 2). One significant unexpected adverse event was classified 
as possibly related to vaccine administration: exacerbation of 
sleep apnea in a cohort 2 volunteer several months after malaria 
(grade 3) adverse events that were definitely, probably or possibly 
related to vaccine administration.
Neither the number nor the severity of adverse events varied 
significantly among cohorts, indicating that the expression of 
hGM-CSF in the muscle or any resulting systemic distribution 
did not affect tolerability (Fig. 2). In three of the cohorts, more 
adverse events followed the first immunizations, but this was not 
statistically significant in the trial as a whole.
Unsolicited adverse events. Unsolicited adverse events were 
recorded by asking an open-ended question “do you have any 
additional symptoms?” There were four clinically significant 
Figure 1. Flow diagram of volunteers. 102 volunteers provided informed consent and 57 passed screening. Thirty-three were excluded because: HLa 
type not needed (11), abnormal laboratory results (9), finding on medical history (3), finding on physical exam (3), HIV positive (1), conflicting concomi-
tant medication (1), leaving area (1), military supervisor denied approval (1), non-compliance with appointment schedule (1), problem with method 
of compensation (1), enrolled in another protocol (1) and 12 withdrew of their own accord without specifying a reason. During the interval between 
screening and the first immunization, ten additional volunteers were dropped because: military supervisor denied approval (2), military transfer 
(3), pregnancy (1) or withdrew of their own accord without specifying a reason (4). Forty-six of the remaining 47 enrolled volunteers were assigned 
sequentially to cohorts 1–4. One volunteer in cohort 3 withdrew after the first immunization (personal reasons not related to adverse events) and was 
not replaced, one volunteer withdrew from the infectivity controls in cohort 1 (personal reasons not related to adverse events) and was replaced from 
the enrolled volunteers (denoted by an asterisk*), and one volunteer withdrew from the infectivity controls of cohort 4 prior to challenge (personal 
reasons not related to adverse events).
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203) with a normal CPK 7 d after the first immunization and at 
all-time points after the second and third immunizations, and 
the second noted 111 d after the third immunization (20,077 
IU/L) with a normal CPK 48 d after the third immunization 
and at all prior time points. There was one elevated CPK in a 
volunteer receiving 100 μg of GM-CSF, with an elevation 28 
d after the third immunization (15,894 IU/L) with a normal 
CPK 14 d after the third immunization and at all prior time 
points. Finally, there were two events in volunteers receiving 
500 μg hGM-CSF, one with an elevation noted 14 d after the 
second immunization (5,954 IU/L) with a normal CPK 7 d 
after the second immunization and at all prior and subsequent 
time points, and the second noted in another volunteer 7 d after 
the second immunization (2,697 IU/L) with a normal CPK 2 d 
after the second immunization and at all prior and subsequent 
time points. Due to the roughly equal distribution of CPK 
elevations among vaccine recipients and controls, to the appar-
ently random timing with respected to immunizations (follow-
ing first, second or third immunizations), rapid normalization 
and lack of recurrence on re-challenge with vaccine, and to the 
proximity of each elevation to newly-initiated vigorous, military 
style exercise programs, these CPK elevations were classified as 
possibly related to immunization.
Due to concerns that DNA vaccines might induce 
autoimmune responses,40 we measured anti-double stranded 
DNA antibodies at 0, 4, 8, 12, 24 and 52 weeks and found no 
abnormalities (Fig. 3A). Based on similar concerns, we measured 
infection associated with a 15 pound weight gain (categorized as 
a serious adverse event, due to accelerating the need for hospital 
admission for corrective surgery).
Laboratory tests. Laboratory tests were assessed on days 0, 
2, 7, 14 and 28 relative to each of the three immunizations and 
also at the end of the study (week 52). These were complete 
blood count (CBC), urinalysis, and a chemistry panel including 
creatine phosphokinase (CPK), alkaline phosphatase, biliru-
bin, lactate dehydrogenase, alanine aminotransferase, aspartate 
aminotransferase, blood urea nitrogen and creatinine. There 
were no clinically significant abnormalities in any of these tests 
classified as definitely, probably or possibly related to vaccine 
administration except for CPK elevations (see below), and there 
were no trends observed when cohort means were assessed other 
than a trend of decreasing hemoglobin in both vaccinees and 
controls that was temporally related to the large blood draws 
required for lymphocyte collections and a trend of decreasing 
bilirubin during the first half of the study that was probably 
also related to blood drawing, in both cases with cohort means 
returning to baseline during follow-up. There were seven find-
ings of elevated CPK. All seven coincided with the onset of 
a vigorous exercise program by the volunteer, and other than 
minor myalgia in some instances, there were no signs or symp-
toms of these elevations. Two CPK elevations were in control 
volunteers so could not be linked to the vaccine. Two CPK ele-
vations were in volunteers receiving 20 g hGM-CSF, one noted 
14 d after the first immunization (9,671 IU/L, normal range ≤ 
Table 1. Demographic data for enrolled volunteers
Cohort 1 Cohort 2 Cohort 3 Cohort 4 All
Vaccinees 8 8 8 8 32
Male 5 5 4 4 18
Female 3 3 4 4 14
Infectivity controls 3* 3 3 4 13
Male 2 2 1 3 8
Female 1 1 2 1 5
Immunological controls 1 1
Male 1 1
age (mean, range)
Vaccinees 39.9 (30–48) 29.6 (21–50) 32.9 (23–45) 37.4 (22–49) 34.9 (21–50)
Infectivity controls 24.3 (23–26) 28.0 (22–36) 43.3 (42–44) 34.5 (30–41) 32.7 (22–44)
Immunology control 42.0 42.0
ethnicity
american Indian/Native american 0 0 2 0 2
asian/pacific Islander 0 1 0 0 1
african american 3 1 3 4 11
caucasian 7 8 5 7 27
Hispanic 0 1 1 0 2
Other 1 0 0 2 3
Totals 11 11 11 13 46
* One infectivity control withdrew prior to the challenge from cohort 1 and is not included in this table; thus the number of volunteers listed is 46, one 
less than the number enrolled (47).
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Table 2. Number of volunteers experiencing solicited local and systemic adverse signs and symptoms (days 0–28 post immunizations 1 and 2, and 
days 0–14 post immunization 3)
Cohort 1 n = 8 Cohort 2 n = 8 Cohort 3 n = 8 →7 Cohort 4 n = 8
Sign or 
Symptom
DNA1 DNA2 DNA3 DNA1 DNA2 DNA3 DNA1 DNA2 DNA3 DNA1 DNA2 DNA3 Total
LOCAL n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 n = 7 n = 7 n = 8 n = 8 n = 8
Tenderness 6(75%) 5(62%) 4(50%) 7(88%) 5(63%) 4(50%) 6(75%) 6(86%) 5(71%) 8(100%) 7(88%) 6(75%) 69(62%)
pain 2(25%) 2(25%) 1(13%) 2(25%) 1(13%) 1(13%) 2(29%) 2(25%) 1(13%) 14(13%)
ecchymosis 2(25%) 3(38%) 2(25%) 1(13%) 8(7%)
Induration 2(25%)* 1(13%)* 1(13%)* 1(13%)* 1(13%)* 1(13%)* 7(6%)
erythema 1(13%) 2(25%) 1(13%) 1(13%) 1(13%) 1(14%) 1(13%) 1(13%) 1(13%) 10(9%)
swelling 1(13%)* 1(1%)
pruritis 1(14%) 1(1%)
Decreased arm 
range
1(13%) 1(1%)
Ipsilateral neck 
muscle ache
1(14%) 1(1%)
Total Local 
AEs
14 13 9 10 6 4 8 7 9 13 10 9 112
Rate (AEs/
immuniz)
1.75 1.63 1.13 1.25 0.75 0.50 1.00 1.00 1.29 1.63 1.25 1.13
sYsTeMIc
Myalgia 1(13%) 1(13%)
1(13%)
1(13%)
4(8%)
Malaise 1(13%) 3(38%) 1(14%) 5(10%)
Headache 1(13%) 1(13%) 1(13%) 3(38%) 1(14%) 2(25%) 1(13%) 10(20%)
Diarrhea 1(13%) 1(13%) 1(13%) 3(6%)
Nausea 1(13%) 1(13%) 1(14%) 1(13%) 4(8%)
Vomiting 1(14%) 1(2%)
Fatigue 2(29%) 2(4%)
arthralgia
1(13%)
1(13%)
1(14%) 3(6%)
chills 1(13%) 3(38%) 4(8%)
Lightheaded 1(13%) 1(13%) 1(13%) 3(6%)
chest tight-
ness
1(13%) 1(2%)
Respiratory 
symptoms
4(50%) 4(57%) 2(25%) 10(20%)
Fever 1(13%) 1(2%)
Total 
Systemic AEs
3 2 1 2 3 2 21 11 2 1 2 1 51
Rate (AEs/
immuniz)
0.38 0.25 0.13 0.25 0.38 0.25 2.63 1.57 0.29 0.13 0.25 0.13
Total All AEs 17 15 10 12 9 6 29 18 11 14 12 10 163
(Upper half of table) 112 local adverse events were reported after DNa immunizations, all occurring and resolving within the first 0–7 d. all were 
classified as directly related to immunization. Of these, 104 were classified as mild (grade 1), and 8 were classified as moderate (Grade 2, denoted by an 
asterisk*). (Lower half of table) 51 systemic adverse events were reported days 0–28 after immunizations 1 and 2 and days 0–18 after immunization 
3; of these, none were classified as directly related to immunization and three were classified as probably related to immunization (bold). The rest (48) 
were classified as possibly related to immunization, including 47 assessed as mild (grade 1), and one case of vomiting assessed as moderate (grade 2) in 
severity. Because the 48 possibly-related adverse events all appeared more likely associated with intercurrent illnesses than immunization (e.g., cluster 
of respiratory symptoms in cohort 3 during the first two immunizations, which took place during the months of January and February, respectively), 
the systemic adverse event rates listed in the table are likely overestimates of the true rate of vaccine-related systemic adverse events.
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(Fig. 4A). The addition of the hGM-CSF plasmid to the vaccine 
did not appear to influence the extent of boosting of antibodies 
on exposure to malaria, as seen by comparing boosting among 
the four cohorts (Fig. 4B).
IFA assays. IFA assays to sporozoites and blood stage parasites 
were performed at the same time points as ELISAs. There were no 
significant increases in antibody responses to whole sporozoites 
or blood stage parasites for any of the volunteers comparing pre- 
and post-immunization sera (Fig. 5). Cohort 1 was also assessed 
for antibodies to liver stage parasites at the same time points, 
and, as for sporozoites and blood stages, there were no significant 
increases in antibody responses (Fig. 5).
Exposure to malaria parasites during challenge induced sig-
nificant increases in antibody titers to sporozoites, liver stage 
and blood stage parasites (p = 0.004 for each, after correction for 
multiple comparisons). The fold increase recorded was similar in 
vaccine recipients and in controls.
IFN-γ ELISpot assay. ELISpot assays were conducted using 
fresh PBMCs collected pre-immunization (day 0), 2 weeks 
after the second immunization and 2 weeks after the third 
immunization, by stimulating with individual peptides. After the 
trial was completed, additional ELISpot assays were performed 
with blinded, frozen PBMCs from pre-immunization (day 0), 
pre-challenge (approximately 1 week pre-challenge), 4 weeks 
anti-human GM-CSF antibodies at the same time points in an 
assay developed by Vical, Inc., and again found no abnormalities 
(Fig. 3B). Hemoglobin A1C was measured at screening and at 
week 15 without recording any abnormal values or rising trends 
within cohorts (data not shown).
Overall, the vaccine was very well-tolerated by all recipients, 
with nearly all definitely-related reactogenicity limited to the 
site of immunization, and resolving within two days of vaccine 
administration.
Immunogenicity. ELISA. Antibody responses to four of 
the antigens (PfCSP, PfSSP2/TRAP, Pf EXP1, Pf LSA1) 
were measured pre-immunization, two weeks after the third 
immunization (four days prior to challenge), six weeks after 
the third immunization (25 d post challenge) and 8 weeks after 
the third immunization (38 d post challenge). No ELISA was 
performed for Pf LSA3. There were no significant increases in 
antibody titers to any of the four vaccine antigens by ELISA 
following MuStDO5 immunization (Fig. 4). Antibody titers 
to the four tested antigens by ELISA were significantly boosted 
by exposure to malaria parasites during CHMI (p < 0.05 after 
correcting for multiple comparisons for all antigens and all 
cohorts except LSA1 for cohort 2, where p = 0.09, and for cohort 
4, where p = 0.07). However, the degree of boosting was not 
significantly different from that seen in the infectivity controls 
Figure 2. Frequency of Mild and Moderate adverse events in cohorts 1, 2, 3 and 4 after each immunization. Local adverse events are shown after each 
DNa immunization, and are grouped according to mild (grade 1) or moderate (grade 2) severity. Increasing doses of hGM-csF-encoding plasmid did 
not affect tolerability.
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15/31 volunteers to multiple class I and/or class II restricted T cell 
epitopes representing all 5 antigens. Responses to CSP occurred 
in 14/31, to EXP-1 and LSA-1 in 12/31, to LSA-3 in 7/31 and to 
TRAP/SSP2 in 4/31 volunteers. Nine of 15 responders produced 
IFN-γ to both class I and II (DR-binding) peptides. Overall, 
positive responses were detected to 38.2% (13/34) of the class 
and 9 weeks after challenge, with all time points from a given 
volunteer assessed simultaneously, to confirm the data from fresh 
assays.
Detailed ELISpot results have been previously published31 and 
are summarized here. Following immunization, positive, antigen-
specific IFN-γ responses were detected by fresh ELISpot assay in 
Figure 3. anti-dsDNa and anti-hGM-csF antibody responses following DNa immunization. anti-dsDNa levels (IU/mL) (A) and anti-hGM-csF levels 
(optical density) (B) were measured at pre-immunization, at 4, 8, 12, 24 and 52 weeks. cohorts 1, 2, 3 and 4 are color-coded. The upper black line in 
each panel represents the division between normal and borderline positive values for these tests. There are no data for the four-week time point for 
anti-dsDNa for cohorts 1 and 2 (data points used in the graph are averages of the values at 0 and 8 weeks). anti-dsDNa levels were measured by the 
National Naval Medical center clinical Laboratory using fresh sera, and the anti-hGM-csF antibodies were measured by Vical Inc., using frozen sera.
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Figure 4. eLIsa antibody responses by antigen and by cohort. (A) The four graphs provide geometric mean antibody titers to csp, TRap/ssp2, eXp1 
and Lsa1, respectively, as measured by eLIsa pre-immunization (pre-Imm), two weeks after the third DNa immunization/pre-challenge (pre-ch), and 
25 d and 38 d after challenge (ch+25, ch+38). cohorts are color-coded, with solid lines representing immunized volunteers, dotted lines represent-
ing infectivity control volunteers. (B) The four graphs provide geometric means of antibody titers to csp, TRap/ssp2, eXp1 and Lsa1 for each cohort, 
respectively. antigens are color-coded, with solid lines representing immunized volunteers, dotted lines representing infectivity control volunteers.
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duration of liver stage development is just over two days13,44 or by 
the induction of sterile immunity to P. knowlesi in non-human 
primates (NHP) where the duration of liver stage development is 
just over five days and thus similar to P. falciparum.16,45-47 In both 
the mouse14 and NHP96 models, protection induced with gene-
based vaccines was dependent on CD8+ T cells that eliminated 
infected hepatocytes by direct cytotoxicity or through an IFN-γ-
mediated mechanism. Thus the development of protective gene-
based platforms protecting humans against P. falciparum should 
be feasible.
With this trial, we took the first steps to clinically develop the 
multi-antigen approach, combining the DNA encoding five pre-
erythrocytic stage antigens into a plasmid mixture (MuStDO5) 
and assessing intramuscular administration via jet injection in 32 
(dropping to 31) healthy, malaria-naïve adults, aiming to induce 
cell-mediated protection. The rationale for multiple antigens was 
based on the genetic restriction of adaptive cell-mediated immu-
nity: since each malaria antigen provides only limited numbers 
of strongly-binding class I epitopes for the diverse MHC antigens 
of the human population, the combination of multiple protec-
tive malaria proteins is likely required to achieve broad popu-
lation coverage.48 In prior non-clinical studies, we have shown 
that multivalent DNA vaccines comprising plasmid mixtures can 
be immunogenic in mice and NHP without significant interfer-
ence,16,45,49,73 although plasmids encoding certain malaria pro-
teins could theoretically suppress the immunogenicity of other 
plasmids if included in the mixture,50 as shown in vitro.51
The first objective of the clinical trial was to explore safety and 
tolerability. The trial demonstrated that the MuStDO5 vaccine 
was both safe and well tolerated and caused no severe or serious 
side effects. Adverse events were mostly mild, mostly local to the 
injection site, and rapidly resolving. Injection of DNA plasmids 
did not induce anti-ds-DNA antibody responses or anti-hGM-
CSF responses, allaying concerns that DNA immunization 
might lead to auto-immunity.52,53 Several immunized volunteers 
developed acute elevations of the muscle enzyme CPK, but these 
events showed no consistent timing with respect to immuniza-
tions, occurred with equal frequency in unimmunized control 
volunteers, and, in each case, followed the initiation of military 
style physical training. Moreover, the degree of CPK elevation 
was consistent with that previously reported for civilians or mili-
tary service members engaging in intense exercise programs,54,55 
so it did not appear that the vaccine had rendered the study sub-
jects more sensitive to exercise-induced muscle damage. None of 
the individuals with elevated CPK in our study had associated 
changes in blood creatinine levels (data not shown), indicating 
that there was no renal insult. Overall, MuStDO5 administra-
tion was safe, consistent with findings from other DNA vaccine 
trials in malaria,29 tuberculosis56 and HIV.57
The second objective was to assess immunogenicity. The 
MuStDO5 vaccine successfully induced IFN-γ responses to each 
of the five antigens; positive responses were detected to 38.2% 
(13/34) of the class I-restricted peptides and to 94.1% (16/17) of 
the class II-restricted peptides tested.31 About half the volunteers 
responded to class I or class II peptides from at least one antigen, 
although only 6/31 (19%) demonstrated class I responses. 
I-restricted peptides (3 for CSP, 1 for SSP2/TRAP, 2 for EXP1, 
5 for LSA1 and 2 for LSA3) and to 94.1% (16/17) of the class 
II-restricted peptides (4 for CSP, 3 for SSP2/TRAP, 2 for EXP1, 5 
for LSA1 and 2 for LSA3). Inclusion of hGM-CSF plasmid, rather 
than improving responses, appeared to inhibit IFN-γ responses to 
class I peptides in cohorts 2, 3 and 4 compared with cohort 1, while 
responses to class II peptides appeared unaffected by the cytokine.
Exposure to malaria following CHMI significantly boosted 
both class I and class II responses, with the number of responding 
volunteers increasing from 15/31 volunteers prior to challenge to 
23/31 volunteers following challenge, with the magnitude of indi-
vidual responses increasing from 2- to 143-fold.31 The magnitude 
of boosting in vaccinees appeared greater than in controls. The 
inhibitory trend shown by hGM-CSF for class I responses prior 
to challenge (3/23 volunteers positive for IFN-γ responses to class 
I in cohorts 2–4 vs. 3/8 in cohort 1, p = 0.15) was enhanced post 
challenge (4/23 volunteers positive for IFN-γ responses to class I 
in cohorts 2–4 vs. 5/8 in cohort 1, p = 0.015), while responses to 
class II peptides remaining unaffected.
Efficacy. Controlled human malaria infection. Thirty-one vac-
cinated and 13 unvaccinated volunteers underwent CHMI as 
previously described41 (8, 8, 7 and 8 vaccinees and 3, 3, 3, and 
4 controls in the four cohorts, respectively). The days to para-
sitemia in cohorts 1–4 are shown in Figure 6 as Kaplan-Meier 
survival curves. The mean days to parasitemia were similar in the 
four cohorts: 10.7, 10.0, 11.1 and 11.1 d, respectively. No volun-
teer was completely protected, and there were no significant dif-
ferences in the mean days to parasitemia for vaccinees relative to 
controls in any of the cohorts, although a trend suggesting delay 
in vaccine recipients was seen in cohort 2 that was not statistically 
significant (p = 0.08).(Fig 7)
Because the proposed mechanism of protection for MuStDO5 
is genetically restricted cell-mediated immunity, we repeated the 
efficacy analysis limited to the volunteers with the two most 
common class 1 antigens among vaccine recipients, HLA-A02 
or HLA-A03, to increase the homogeneity of the study subjects. 
This excluded 7 of 31 vaccine recipients, and 8 of 13 infectivity 
controls. Examining the remaining 24 vaccinees and 5 controls, 
the addition of GM-CSF tended to prolong the days to parasit-
emia (10.4, 10.7, 11.3 and 11.2 d for the four cohorts, respec-
tively), but this was not statistically significant (p = 0.52).
Discussion
The identification of a vaccine approach that successfully tar-
gets liver stage malaria is a critical step in the development of a 
highly protective vaccine. The number of hepatic parasites result-
ing from an infectious mosquito bite is relatively small, probably 
no more than 100,42 and development in the liver is non-patho-
genic. Their elimination prior to transformation into the highly 
pathogenic blood stages would entirely prevent illness. Moreover, 
the roughly five-day span of liver stage development in P. fal-
ciparum appears long enough for cytotoxic or IFN-γ-secreting 
effector cells to work, as demonstrated by the induction of ster-
ile immunity to P. yoelii in BALB/c mice13,14 by immunization 
with PyCSP,14 PySSP243 and PyHep17 (PfEXP1),33,48 where the 
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on challenge indicating a potential benefit of DNA vaccination 
for residents of endemic areas where frequent malaria exposure 
could boost protective responses and accelerate the development 
of naturally acquired immunity. However, non-immunized 
controls were equally boosted by exposure to CHMI. As with 
cellular responses, the low antibody titers indicated the need for 
improved DNA vaccine technologies such as the use of superior 
adjuvants, or the use of improved regimens such as DNA priming 
followed by viral vector boosting.
The third objective was to assess protection. The challenge 
results showed no protection, neither sterile protection nor sig-
nificant delay in the onset of parasitemia. A post-hoc analysis 
of volunteers with A02 and/or A03 class I supertype alleles in 
cohorts 1–4 showed the same negative results.
A fourth objective was to determine if immune responses and 
protection could be enhanced by co-administration of plasmid 
expressing a human cytokine. A sixth plasmid encoding hGM-
CSF was added to MuStDO5 using a dose-escalation design, 
based on murine studies demonstrating a doubling of protection 
from 28% to 58% when a DNA plasmid encoding murine 
The responses were boosted by exposure to malaria challenge, 
a potentially useful attribute for any vaccine used in endemic 
areas where frequent exposure to the parasite could boost the 
protection induced by such a vaccine. The results also indicated 
that responses to CSP were not inhibited by inclusion in the 
five-plasmid cocktail when historically compared with the CSP 
plasmid administered alone in earlier studies.31 However, cellular 
responses were generally of low magnitude, ranging from 12 to 
96 net spot forming cells (sfcs)/106 PBMCs (geometric mean, 
23.4), and likely much higher responses are needed to protect. 
This could be achieved by a number of improvements, such as 
codon-optimization to enhance expression in mammalian cells,58 
delivery via electroporation to improve cellular uptake or use of 
an adjuvant superior to GM-CSF.59
Antibody responses were also measured in this trial. As has 
been found with some other DNA vaccines including our earlier 
clinical studies with the monovalent PfCSP-encoding plasmid, 
these responses were negligible, with no significant pre-/post-
immunization differences recorded. Like cellular responses, 
antibody responses, particularly against PfCSP, were boosted 
Figure 5. Immunofluorescent antibody responses to sporozoites, liver and blood stages. The figures show IFa titers against sporozoites, liver stages 
and blood stages, measured at pre-immunization (pre), week 10 (pre-challenge) and week 14 (25 d after challenge). Time points are color-coded in 
different shades of black and gray. cohorts 1, 2, 3 and 4 were tested against sporozoites and blood stages and cohort 1 against liver stages. Infectivity 
controls were measured at the same time points. *Volunteer not tested.
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the avidity of elicited immunoglobulin G for SIV envelope 
glycoproteins and to enhance antibody-dependent cellular 
cytotoxicity in association with significant improved efficacy 
against SIV challenge.72 In other models however, GM-CSF 
DNA has been reported to both augment and suppress cellular 
or humoral responses, according to the antigen, mouse strain and 
whether or not it is combined with other cytokines.73-76 Human 
studies of GM-CSF DNA have been restricted to cancer patients, 
where hGM-CSF-encoding plasmid has been well-tolerated77,78 
and may have shown some benefit.79 This is the first study where 
it was used in healthy humans to enhance a prophylactic vaccine 
against an infectious agent.
The finding that GM-CSF offered no apparent benefit, and 
indeed may have diminished immunogenicity for class I responses 
following immunization and following boosting on exposure to 
malaria challenge,31 was unexpected, contrasting with our find-
ings in animal malaria models36,80 as well as those of Li et al.70 
One potential explanation could be non-optimal expression lev-
els. When we studied the injection of murine GM-CSF DNA in 
mice, it was not possible to detect systemic levels of the protein.39 
While a likely advantage with regard to tolerability, this may 
GM-CSF was added to a protective DNA plasmid encoding 
P. yoelii CSP.36 In the murine model, GM-CSF DNA induced a 
30-fold increase in antigen-specific antibodies, a 5-fold increase 
in antigen-specific IFN-γ spot forming cells and a significant (p < 
0.05) increase in protection using a DNA/poxvirus prime/boost 
regimen.60
Most prior experience with GM-CSF has been with the recom-
binant protein, approved for use in stem cell and bone marrow 
transplant patients to reconstitute the myeloid series (sargramos-
tim) or as part of an immunotherapy regimen for prostate cancer 
(sipuleucel-T). Recombinant GM-CSF enhances phagocytosis 
of P. falciparum blood stage parasites by human neutrophils,61 
has been shown to protect against murine malaria in combina-
tion with the synthetic peptide met-enkephalin62 and has been 
used to enhance immunogenicity of plasmid malaria vaccines in 
chimpanzees.63
The DNA encoding GM-CSF has previously been used as 
an adjuvant to recruit dendritic cells to the site of an immune 
response64 and to enhance the immunogenicity and protection 
in murine and NHP malaria models including in neonatal 
mice.36,60,65-71 GM-CSF DNA has also been shown to enhance 
Figure 6. Vaccine efficacy by Kaplan-Meier plot. The figure present parasitemia-free survival curves (Kaplan-Meier) for immunized (solid lines) and 
infectivity controls (dotted lines) for the four cohorts, respectively, based on microscopic examination of peripheral blood smears. Log rank test was 
used to test the statistical significance between the two groups. There was no significant difference in time to parasitemia between immunized volun-
teers and control volunteers.
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the Army, the Bureau of Medicine and Surgery of the US Navy 
and the internal policies for human subject protections and the 
standards for the responsible conduct of research of the Naval 
Medical Research Center (NMRC) and US Army Medical 
Research and Materiel Command (USAMRMC). NMRC holds 
a Federal Wide Assurance (FWA 00000152) from the Office 
for Human Research Protections (OHRP). All NMRC key 
personnel contributing to or performing human research efforts 
were certified as having completed mandatory human research 
ethics education curricula and training under the direction of the 
NMRC Office of Research Administration (ORA) and Human 
Subjects Protections Program (HSPP). Written informed consent 
was obtained from all subjects before screening and enrollment 
in this study. The trial was performed under US Food and Drug 
Administration Center for Biologics Evaluation and Research 
(CBER) Investigational New Drug Application BB-IND 8687, 
sponsored by Vical, Inc.
Human subjects recruitment. Volunteers were pre-screened 
by telephone under a separate screening protocol and if meet-
ing minimal enrolment criteria (age 18–50, good health, avail-
ability over the time course of the trial, no plans for pregnancy/
lactation) were invited to the NMRC Clinical Trials Center for 
screening. After obtaining informed consent, volunteers provided 
a medical history, received a physical examination and labora-
tory testing for complete blood count (CBC), serum biochem-
istries (blood urea nitrogen, creatinine, AST, ALT, CPK, LDH, 
alkaline phosphatase, bilirubin), hemoglobin A1C and serologic 
tests to characterize their anti-dsDNA, anti-hepatitis B surface 
antigen, anti-hepatitis B core antigen, anti-hepatitis C and anti-
HIV serologies. Volunteers were excluded if they had a history of 
malaria, travel to a malaria-endemic area within the previous 12 
mo, had plans for pregnancy or fathering a child, had evidence 
of active hepatitis or HIV infection, were anti dsDNA positive, 
had a history of splenectomy or were positive on P. falciparum 
sporozoite immunofluorescence test (IFAT). Volunteers were 
selected according to HLA type, since T cell responses were mea-
sured by stimulating PBMC with a limited repertoire of HLA 
class I and II alleles for which strongly-binding peptides had 
been identified from the five antigens. Distribution goals were as 
follows: HLA-A02 supertype (15 class I peptides available from 
CSP, SSP2/TRAP, EXP1, LSA1 and LSA3) – at least 3 vaccinees 
and 1 immunological control per cohort; HLA-A03/11 super-
type (7 class I peptides available from CSP, SSP2/TRAP, EXP1 
and LSA1) at least 2 vaccinees and 1 immunological control 
per cohort; HLA-A01, HLA-B07 and HLA-B08 supertypes (12 
additional class I peptides) to fill remaining slots. Class II typing 
was not performed and did not influence cohort assignment (a 
set of 17 DR-binding peptides from the five antigens was used for 
testing in all volunteers).
Group assignment. Volunteers were sequentially allocated 
to the staggered vaccine cohorts as they met eligibility require-
ments, filling each cohort in turn, with the only restriction being 
to meet the target HLA A02 and HLA A03 super types numbers 
described above. Thus, if HLA targets for a cohort had not been 
met, eligible volunteers lacking the sought-for allelic family were 
moved to the next cohort.
indicate that at the site of induction for the immune response, 
which could be at the injection site, regional lymph nodes or 
more distant splenic or hepatic sites, GM-CSF levels were too low 
or transient to impact the induction of the immune response. On 
the other hand, the trend toward a delay in the onset of parasit-
emia in cohort 2 that was not accentuated with higher hGM-CSF 
doses in cohorts 3 and 4 raises that possibility that tissue levels of 
hGM-CSF could also have been too high, and that lower doses 
might have been more effective.
As second explanation for our results could be that GM-CSF 
was expressed either too early or too late relative to the malaria 
antigens and that staggered administration would have been 
more effective (Hartikka J., unpublished data). For example, 
GM-CSF might trigger the early maturation of dendritic cells, 
without allowing the opportunity for appropriate antigen uptake 
and presentation. However, the injection of the plasmid encoding 
hGM-CSF into humans either prior to or following the injection 
of MuStDO5 would be impractical, even if it improved the qual-
ity of immune response.81 In addition, plasmids encoding other 
cytokines have significantly enhanced immunogenicity when 
co-administered with a DNA vaccine, including IL-15,82,83 IL-12 
and IL-28B,84 high mobility group box 185 and RANTES,86,87 
and may be preferable to GM-CSF. Alternatively, an adjuvant 
that acts through an immunostimulatory mechanism could 
bypass the need to include single cytokines as co-treatments.
In summary, the MuStDO5 vaccine trial represented a first 
step in the development of the DNA vaccine approach to inducing 
protective cell-mediated immunity targeting multiple pre-eryth-
rocytic stage antigens. The vaccine was safe and well-tolerated 
and induced IFN-γ responses to all five malaria proteins, sup-
porting the multi-antigen strategy, but it was insufficiently 
immunogenic, and GM-CSF did not enhance immunogenicity 
or protection, contrary to expectations based on animal models. 
Key approaches to improving DNA vaccines, already under study 
at the time the MuStDO5 trial was performed, include codon 
optimization and other enhancements to the plasmid, use of more 
compatible plasmid mixtures to eliminate interference, electro-
porated administration, use of more concentrated formulations 
to allow delivery of higher plasmid doses, co-administration with 
alternative cytokine plasmids, immunostimulatory adjuvants or 
boosting with recombinant viral vectors such as adenovectors. In 
follow-on studies of DNA vaccines for the prevention of malaria, 
we have used codon optimized plasmids, higher doses of DNA (1 
mg per plasmid), and boosting with recombinant adenovirus vec-
tors; these three changes, planned at the time that the MuStDO5 
trial was performed, have resulted in improved immunogenicity 
and protection, to be reported in future publications.
Methods
Human subjects research. Ethical review. This study was 
conducted in accordance with federal regulations regarding 
the protection of human participants in research including 32 
CFR 219 (The Common Rule), The Nuremberg Code, The 
Belmont Report and all pertinent regulations of the Department 
of Defense, the Department of the Navy, the Department of 
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Local adverse events were graded according to specific criteria 
(NCI Common Toxicity Criteria Version 2.0).88 Systemic adverse 
events were graded as mild (no interference with the activities 
of daily living, no intervention required), moderate (minimal 
intervention required to increase comfort and to carry out the 
daily activities) or severe (preventing daily activities). Each 
adverse event was classified as definitely (temporal relationship, 
no alternate etiology), probably (temporal relationship and 
alternative etiology apparent but less likely), possibly (temporal 
relationship but alternative etiology more likely) related or 
unrelated (no temporal relationship or definitive alternative 
diagnosis) to vaccine administration, and was made according 
to the principal investigator’s medical judgment in coordination 
with other physicians evaluating the adverse event.
Assessment of efficacy. Volunteers were challenged with malaria 
18 d after their third DNA immunization by bites of Anopheles 
stephensi mosquitoes infected with the P. falciparum NF54 strain 
(from which the 3D7 clone is derived)89 in a secure room in the 
joint Walter Reed Army Institute of Research (WRAIR)/NMRC 
insectary. The infected mosquitoes were produced by NMRC at 
the Biological Research Institute, Rockville, MD and transported 
to WRAIR/NMRC the morning of the challenge. For each 
volunteer, five mosquitoes were allowed to feed for five minutes, 
after which they were dissected to determine if they had taken 
a blood meal and had a minimum 2+ salivary gland infection 
for sporozoites.41 If required, additional mosquitoes were allowed 
to feed until five infected mosquitoes with a 2+ salivary score 
had fed on each volunteer. Starting on day 7 after challenge, 
volunteers were housed at the Navy Lodge on the campus of the 
National Naval Medical Center in Bethesda, Maryland. Each 
volunteer had a daily Giemsa-stained thick blood film examined 
for the presence of asexual malaria parasites by a certified expert 
microscopist, and confirmed by a second reader. The identity 
of immunized and non-immunized volunteers was not known 
by the microscopists reading the malaria smears. Symptomatic, 
undiagnosed volunteers had additional smears performed at the 
discretion of the study doctor, not to exceed one smear every 8–12 
h. Volunteers who developed malaria were treated with a standard 
oral dose of chloroquine phosphate (total 1500 mg base given in 
divided doses: 600 mg initially followed by 300 mg given 6, 24 and 
48 h later) under direct supervision with back-up drugs available 
in case of intolerance. Vomiting was treated with prochlorperazine 
if indicated to assist with retention of chloroquine doses.
Vaccines. Vaccine composition. MuStDO5 contained 5 DNA 
plasmids encoding genes for P. falciparum proteins expressed 
during the sporozoite and liver stages.26,27,49 VCL-2510 (PfCSP), 
VCL-2519 (PfSSP2), VCL-2523 (Pf EXP1), VCL-2551 (N’C-
term Pf LSA1) and VCL-2556 (Pf LSA3). Sequences were based 
on the 3D7 strain of P. falciparum. All five transgenes were man-
ufactured by Vical, Inc. The clinical testing of plasmid VCL-
2510 containing the full-length gene of P. falciparum CSP has 
been previously reported.28,29,31,90 The MuStDO5 vaccine was 
extensively tested for safety in mice and rabbits39 and was found 
to be safe and well tolerated without any evidence of inducing 
autoimmunity. Diagrams of the five plasmids are provided in 
Figure 8. Each is a closed circular DNA plasmid produced under 
Blinding. This was an open label clinical trial where the 
researchers and volunteers knew which treatment was being 
administered (there was only one vaccine treatment in each 
cohort, as immunological and/or infectivity controls received no 
injections). However, all laboratory assessments were blinded, 
including the microscopists who undertook diagnosis of malaria 
infection during CHMI.
Sample size and statistical analysis. This was the first safety and 
immunogenicity study in humans of a multivalent DNA malaria 
vaccine with or without a recombinant plasmid expressing hGM-
CSF; for this reason, the sample size of each study group was lim-
ited by safety considerations and was not calculated with regard 
to power for demonstrating a specified level of efficacy. Vaccine 
efficacy was represented by Kaplan-Meier plots. Log rank tests 
were used to compare time to parasitemia between control and 
immunized volunteers for each cohort, and time to parasitemia in 
A02 and A03 volunteers comparing between cohorts. After nor-
malizing time to parasitemia data for the four cohorts for A02 and 
A03 volunteers to a common mean, the Mann-Whitney U test was 
used to compare vaccine recipients and controls. The sign rank test 
was used to see whether the differences in ELISA and IFA between 
pre- and post-immunization, and between pre- and post-challenge 
were equal to 0. The Wilcoxon test was used to evaluate whether 
the boosting effect for antibodies (difference in immune measures 
between pre- and post-challenge) was different between control 
and immunized volunteers for each cohort. ELISA and IFA data 
were log transformed prior to the analysis. The Bonferroni method 
was used to adjust P-values for multiple comparisons. Two-sided p 
< 0.05 was considered significant in all tests.
Assessment of safety. Vaccine recipients were observed for 30 
min after each immunization and returned on days 2, 7, 14 and 
28 for follow-up. Solicited adverse events were recorded by direct 
questioning on days 0, 2, 7, 10, 14 and 28 following the first and 
second immunizations and on days 0, 2, 7, 10 and 14 following 
the third immunization, and by a diary card filled out days 1 
through 7 after each immunization to record oral temperature. 
Solicited adverse events were malaise, fatigue, fever (subjective), 
chills, rigors, headache, dizziness, myalgia, arthralgia, cough, 
nausea, vomiting, abdominal pain and dark urine while unsolic-
ited adverse events were identified by the open-ended question, 
“Have you experienced any other symptoms?” The injection sites 
were observed for tenderness, swelling, warmth, induration and 
erythema. Associated axillary lymphadenopathy and limitation 
of arm movement were also assessed by examination. Safety labs 
were measured on D0, 2, 7, 14 and 28, and included complete 
blood count (CBC), urine analysis and blood chemistries (same 
as for screening, see above). These safety labs were repeated again 
on day 49 after the last vaccination. An autoimmunity panel 
(anti-dsDNA ELISA, anti-hGM-CSF) was measured on day 28 
after each vaccination and in some volunteers at 24 and 52 weeks 
after the last vaccination. Hemoglobin A1C, first performed at 
screening, was repeated at 7 weeks after the last immunization. 
Monitoring for serious adverse events was conducted throughout 
the trial (hospitalization, persistent or significant disability, life 
threatening events such that failure to intervene could result in 
hospitalization or death).
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(cohort 3) or 500 μg (cohort 4). The vaccine was injected into 
the deltoid muscle by needleless jet injection (Biojector® 2000, 
Bioject, Inc.). Pressure was applied to each injection site for one 
minute immediately following actuation of the device to limit 
hematoma formation. Three injections were given at 0, 4 and 8 
weeks, alternating arms between injections.
Laboratory testing. HLA typing. Class I intermediate resolu-
tion molecular typing was performed by Georgetown University 
C. W. Bill Young/Department of Defense Marrow Donor 
Program. Molecular HLA class I typing was performed using 
the Sequence Specific Oligonucleotide Probe (SSOP) method. 
Volunteers were assigned HLA types (HLA A and HLA B) at the 
intermediate resolution with their respective HLA allele codes 
based on the code list at: (www.bioinformatics.nmdp.org/Allele_
Code_Lists/Index.html).
Microscopy. Two slides were made for each blood sample. Ten 
μl of blood was smeared onto each of two 1-cm × 2-cm rect-
angles on each slide. The slides were dried on a 37°C heat block 
for 5–10 min. Slides were stained with fresh Giemsa stain (4% 
solution of stain in phosphate buffered saline pH 7.0–7.2) for 
45–60 min, rinsed with water and allowed to dry. The slides were 
viewed under oil immersion at a total magnification of 1,000×. 
For asymptomatic individuals, 360 fields were read in 5 verti-
cal passes. For symptomatic individuals, 1,080 fields were read 
in approximately 15 vertical passes. A volunteer was determined 
cGMP from bacterial cells grown in kanamycin selective media. 
Expression is controlled by the promoter/ enhancer of the human 
cytomegalovirus immediate early (CMV IE) gene. Each plas-
mid contains two open reading frame sequences: one encodes 
the kanamycin resistance protein which is expressed in bacterial 
cells and the other encodes a human tissue plasminogen activator 
protein (hTPA) leader / malaria fusion protein which is expressed 
in mammalian cells.
Vaccine formulation. The MuStDO5 vaccine was vialed at 3 
mg/mL (600 μg/mL each plasmid) in phosphate buffered saline 
(PBS) containing 10 mM sodium phosphate in 0.9% sodium 
chloride solution, 1.5 mL total per vial. To prepare the vaccine 
for administration, 0.3 mL was added to the MuStDO5 vial from 
one of four other vials containing, respectively, 0, 0.12, 0.6 or 3 
mg/mL PBS of a sixth plasmid, VCL-1723 (hGM-CSF), creating 
final concentrations of each malaria plasmid of 500 μg/mL, and 
a final concentration of hGM-CSF plasmid of 0, 20, 100 or 500 
μg/mL (total plasmid concentration of 2.5, 2.52, 2.6 or 3 mg per 
mL of solution). Vaccine was withdrawn from each vial imme-
diately after mixing, each mL containing 2.5 mg MuStDO5 
combined with 0, 20, 100 or 500 μg of hGM-CSF, for adminis-
tration to cohorts 1–4 respectively.
Vaccine administration. Four cohorts (each n = 8 vaccinees) 
were immunized with 2.5 mg of the 5 plasmid mixture together 
with GM-CSF at 0 μg (cohort 1), 20 μg (cohort 2), 100 μg 
Figure 7. Days to parasitemia of combined HLa a02 and a03 volunteers. Days to parasitemia are shown in HLa a02 and a03 volunteers, comparing 
vaccinees (gray bars) and infectivity controls (white bars). since the mean day of onset of parasitemia was different for each of the four challenges, 
days prior to or following the group-specific mean day of onset were calculated for each volunteer in order to standardize. Data were then combined 
on a common timeline with mean day of onset for each cohort set to zero. There were no statistically significant differences in time to parasitemia 
between cohorts (p = 0.52, Wilcoxon) or between immunized volunteers and infectivity controls (p = 0.32, Mann-Whitney).
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of parasites observed in 15 passes (1.35 μL 3), providing a limit 
of detection of 1 to 2 parasites/μL. The expert microscopists had 
extensive experience in malaria microscopy and passed a profi-
ciency test on parasite detection.
Antibody assays. Blood was collected in preservative free hepa-
rin, centrifuged, and plasma separated and frozen at -70°C until 
tested. All time-points for a given volunteer were blinded and 
assayed together.
to be parasitemic when two parasites were found and confirmed 
by an expert microscopist during the fixed searching routine. 
The physician on duty was then informed by the microscopist of 
the volunteer’s status and also observed the confirmed parasites. 
Parasitemia for asymptomatic research subjects was calculated 
from the number of parasites observed in 5 passes (0.45 μL 3), 
providing a limit of detection of 4 to 5 parasites/μL, and for 
symptomatic research subjects was calculated from the number 
Figure 8. For figure legend, see page 1580.
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incubated at 37°C for 30 min. Tissue sections were then washed 
and the slides mounted, using Vectashield mounting medium 
(Vector Labs). The stained slides were screened with a Nikon 
Eclipse E600 epifluorescent microscope.
ELISA. Antibodies were measured by the enzyme-linked 
immunosorbent assay (ELISA) using recombinant proteins 
(0.5 μg/mL for CSP, 1.0 μg/mL for SSP2/TRAP, 2.0 μg/mL 
for EXP1, 4.0 μg/mL for LSA1) as previously described,93,94 
Mean + SD of the OD readings of quadruplicate assays were 
recorded. Samples were considered positive if the mean OD 
value of the plasma sample post-immunization was greater than 
the mean OD plus 2 standard deviations of the plasma sample 
pre-immunization.
Recombinant proteins for ELISA. P. falciparum CSP, SSP2/
TRAP and LSA1 were produced as recombinant proteins in 
E. coli with a HIS
6
-tag added at the C-terminus to facilitate 
purification on a Ni-NTA agarose column. These recombinant 
proteins encoded the following amino acids of their respec-
tive molecules from the 3D7 strain of parasite: PfCSP aa L
19
-
N
405
; PfSSP2/TRAP aa D
48
-K
394
; and Pf LSA1 aa E
1628
-L
1909
. 
Recombinant Pf EXP1 encoding for the full length gene from the 
K1 strain of parasite was expressed in E. coli and was a gift from 
Hoffmann-La Roche, Basel, Switzerland. The further details for 
the plasmid construction, recombinant expression and purifica-
tion of these proteins are available elsewhere.73
Peptides. Peptides were chosen by searching the amino acid 
sequences (P. falciparum strain 3D7) of the five proteins for 
motifs that predict binding to the common HLA class I alleles 
in the study population. Peptides predicted to bind were synthe-
sized and tested in binding assays to determine those with high 
affinity.95 A total of 51 synthetic peptides were selected and stud-
ied in this trial including 34 MHC class I-restricted CD8+ T cell 
epitopes at 8–10 amino acids in length and 17 class II-restricted 
CD4+ T cell epitopes at 20–23 amino acids in length. All pep-
tides were purchased from AnaSpec at > 90% purity. Of the 34 
defined class I-restricted epitopes, 9 were derived from PfCSP, 
6 from PfSSP2/TRAP, 4 from Pf EXP1, 9 from Pf LSA1, and 6 
from Pf LSA3, restricted by 7 different HLA-A and -B supertype 
families.90 Of 17 HLA-DR-restricted epitopes, 4 were derived 
from PfCSP, 3 from PfSSP2/TRAP, 2 from Pf EXP1, 5 from 
Pf LSA1, and 3 from Pf LSA3. As previously described30,31 pep-
tides containing a known HLA-A0201-restricted epitope from 
influenza matrix protein (residues 58–66, GILGFVFTL) and 
Immunofluorescence antibody (IFA) using sporozoites. Serum 
antibody levels were assessed by IFA against air-dried sporo-
zoites. NF54 strain sporozoites from infected mosquitoes were 
suspended in 3% BSA at a concentration of 106 sporozoites per 
mL. An aliquot of 10 μL containing 104 sporozoites was deliv-
ered into each well of the antigen slide. The antigen slides were 
allowed to air dry at room temperature and were kept at -70°C 
until used. An amount of 20 μL of a 2-fold serial dilution of test 
or control serum in PBS containing 2% BSA was added to each 
well of the antigen slides. The slides were incubated for one hour 
at 37°C, washed 3 times in PBS, 5 min each wash. Each well 
was incubated for 30 min at 37°C with 20 μL of a 1:50 dilution 
of FITC-labeled goat anti-human IgG (H+L) (Kirkegarard and 
Perry). The slides were washed again, mounted in a Vectashield 
mounting medium (Vector Laboratories, Inc.) and examined 
under an Olympus UV microscope. Positive control was a serum 
sample from a volunteer immunized with radiation-attenuated 
P. falciparum sporozoites. Seroconversion was defined as a 4-fold 
rise, as compared with the pre-immune plasma, against P. falci-
parum parasites.
Immunofluorescence antibody (IFA) using blood stage parasites. 
Serum antibody levels were assessed as previously described91 using 
the NF54 strain of P. falciparum. Slides were examined under an 
Olympus UV microscope and end-point titers were determined as 
the last dilution above the background that fluorescent parasites 
were observed. Background fluorescence was established for each 
group by the pre-immunization serum (pre-bleed).
Immunofluorescence antibody (IFA) using liver stage parasites. 
Slides containing cryosectioned P. falciparum infected chimp 
liver92 were stored at -80°C wrapped in foil in a plastic bag. Prior 
to IFA, tissue section slides were removed from the freezer and 
placed in a dessicator for equilibration to room temperature. 
Diluted antiserum was then applied to the sections (in a volume 
sufficient to cover the tissue) and the slides were processed as 
previously described.49 Briefly, the slides were incubated for 30 
min. at 37°C in a humidity chamber. Liver section slides were 
placed in a staining dish and washed 3 times for 5 min with PBS. 
A fluorescein-conjugated IgG (Kirkegaard and Perry) was used 
as the secondary antibody. The secondary antibody was diluted 
1:40 into PBS containing 0.02% Evan’s blue. The Evan’s blue 
was added to act as a counterstain and to suppress any autofluo-
rescence in the tissue. The diluted secondary antibody was added 
and the slides placed in a humidity chamber, in the dark, and 
Figure 8 (See previous page). schematic diagram of the DNa gene products. each panel presents the native protein (above) and the protein 
expressed by the DNa (below) for the five vaccine antigens and for hGM-csF. The amino acid length is provided in parentheses to the right of the 
diagram. Identical colors indicate identical sequences. ss = native signal sequence. Tpa = human tissue plasminogen activator leader sequence (in-
creases expression in mammalian cells) (yellow boxes). (A) The pfcsp DNa vaccine includes the full length native sequence csp gene. The locations of 
the endogenous pfcsp signal sequence, the pfcsp repeat region, the pfcsp glycosylphosphatidylinositol (gpi) anchor and a 23 amino acid c-terminus 
insertion derived from the transcriptional terminator of the bovine growth hormone gene (dark blue box) are shown. (B) The pfssp2 DNa vaccine 
includes the full length native sequence ssp2 gene. The locations of the endogenous pfssp2 signal sequence, the pfssp2 repeat region and the pfssp2 
transmembrane region are shown. (C) The pfeXp1 DNa vaccine includes the full length native sequence eXp1 gene. The location of the endogenous 
pfeXp1 signal sequence is shown. (D) The pfLsa1 DNa vaccine includes the full N- and c- termini of the native sequence Lsa1 gene minus the repeat 
region. The locations of the endogenous pfLsa1 signal sequence and the pfLsa1 repeat region are shown. The 727 amino acid deletion encompassing 
the pfLsa1 repeat region is represented by dashes. (E) The pfLsa3 DNa vaccine includes the full length native sequence Lsa3 gene. The locations of 
the pfLsa3 repeat regions are shown. (F) The hGM-csF DNa plasmid includes the full length native sequence human GM-csF gene. a 3 amino acid 
insertion generated during the cloning of the GM-csF plasmid is located at the N-terminal end and is represented by a light blue box (the first few 
amino acids of the native GM-csF protein, MWLQsLLLL, were replaced by MaLWILQsLLLL in the DNa construct).
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a known HLA-A0301-restricted epitope from influenza nuclear 
protein (residues 265–273, ILRGSVAHK) were used as posi-
tive controls, and a peptide containing a known HLA-A0201-
restriction from HIV gag protein (residues 77–85, SLYNTVATL) 
was used as a negative control.
Ex vivo IFN-γ ELISpot assay. The P. falciparum antigen-spe-
cific IFN-γ-producing cells were quantified by ELISpot assay 
after 36 h in vitro stimulation in the presence of 10 μg/ml of 
each peptide (fresh assays, HLA class I-matched peptides tested 
individually) or 5 μg/ml of each peptide (frozen assays, HLA 
class I-matched peptides and DR peptides tested in antigen-spe-
cific pools) as described previously.90 Responses were expressed 
as sfc/106 PBMCs, and were considered significant if: (1) the 
mean number of cells in wells with experimental peptide was sig-
nificantly greater (p < 0.05, student’s T test) than in wells with 
control peptide; (2) the net sfcs/well (mean sfcs in experimental 
peptide wells minus mean sfcs in control peptide wells) was ≥ 
5 sfcs/well; and (3) stimulation index (the ratio of mean sfcs in 
experimental peptide wells to mean sfcs in control peptide wells) 
was greater than 2.0. IFN-γ responses were considered to be sig-
nificantly enhanced by challenge if the number of IFN-γ sfcs/106 
PBMCs was at least 2 times higher than that before the challenge.
Anti-human GM-CSF. An ELISA protocol specific for the 
detection of human anti-human GM-CSF immunoglobulin G 
(anti-hGM-CSF IgG) was developed at Vical Inc. A lyophilized 
plasma specimen was obtained from the National Institute of 
Biological Standards and Control (NIBSC) and was used as a 
positive control for the assay. Normal human sera obtained from 
Vital Products were used as negative control specimens. A net 
specific signal was obtained by subtracting non-specific binding 
in uncoated wells from the signal of wells coated with recombi-
nant human GM-CSF (hGM-CSF) antigen.
Recombinant human GM-CSF (Fitzgerald) was coated on 
96-well ½ area plates (Costar cat #3690) at a concentration of 1 
μg/mL in carbonate buffer and incubated overnight at 4°C. Blank 
wells coated with carbonate buffer without antigen were also pre-
pared to test non-specific binding of the samples. The plates were 
then washed with PBS+ 0.05% Tween-20 (PBST), blocked with 
5% nonfat dry milk in PBS and incubated at room temperature 
for 60 min. The plates were washed with PBST and then incu-
bated at 37°C for 1 h with 50 μL of specimen per well diluted 
in 1% milk block. Again the plates were washed with PBST, 
incubated at room temperature for 1 h with 50 μL of secondary 
antibody [goat anti-human IgG (heavy and light chains) alkaline 
phosphatase-conjugate (AP), Bio-Rad 170–6521] diluted 1:1000 
in 1% milk block. Plates were washed with PBST. Substrate 
[p-nitro phenyl phosphate, PNPP, (Bio-Rad, 170–1063)] was 
added, developed for 30 min and optical densities determined at 
a 405 nm wavelength using a microplate reader and SoftmaxPro 
software. Net ODs were determined for each sample by subtract-
ing non-specific ODs (carbonate buffer without antigen wells) 
from corresponding specific ODs (coated antigen wells).
Four criteria were used for identifying and reporting a positive 
sample: OD signal > 0.5 OD units in a coated well with a 1:10 
diluted sample, a net OD signal of > 0.2 OD units for a 1:10 
diluted sample, a positive sample titer compared with the positive 
control, and a > 4 fold increase in net OD signal between pre and 
post injection samples. 
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